This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Vapotherm (VAPO) Aandelenoverzicht

A medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. Meer informatie

VAPO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

Negatief eigen vermogen

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 10.3% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $14M )

VAPO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW444,721 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

444,721 investors already sharing narratives

View all narratives

Vapotherm, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Vapotherm
Historische aandelenkoersen
Huidige aandelenkoers	US$2.17
52 Week Hoogtepunt	US$3.44
52 Week Laag	US$0.70
Bèta	-1.1
1 maand verandering	0.59%
3 maanden verandering	2.60%
1 Jaar Verandering	-22.22%
3 jaar verandering	-98.97%
5 jaar verandering	-97.04%
Verandering sinds IPO	-98.30%

Recent nieuws en updates

Recent updates

Seeking Alpha • Feb 08

Vapotherm announces $23M private placement

Global medical technology company, Vapotherm (NYSE:VAPO) has entered into a securities purchase agreement with investors through a private placement financing for gross proceeds of ~$23M. Pursuant to the agreement, the company agreed to issue 17.5M shares and pre-funded warrants to purchase up to 4.4M shares. The pre-funded warrants will have a term of 30 years and an exercise price of $0.001 per share. Closing expected to occur on February 10, 2023. Net proceeds from the offering primarily for sales and marketing, working capital, and other general corporate purposes. Stock trades 8% higher.

Seeking Alpha • Nov 02

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Vapotherm press release (NYSE:VAPO): Q3 GAAP EPS of -$0.98 misses by $0.20. Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M. Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94M consensus.

Seeking Alpha • Aug 04

Vapotherm draws downgrade at William Blair after 2Q results

Vapotherm, Inc. (NYSE:VAPO), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave. However, the team remains optimistic about the benefit Vapotherm (VAPO) can count on due to the sizable installed base established during the COVID. In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease. However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty. Wall Street has remained bullish on Vapotherm (VAPO) stock, with an average rating of Buy from analysts, while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market, continued to rate Vapotherm (VAPO) a Strong Sell since March.

Seeking Alpha • May 11

Vapotherm: Out Of Air

Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.

Analyse-artikel • Jan 24

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Seeking Alpha • Jul 11

Vapotherm: Hardly Breathing Room

Vapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses. Given all of this, I am not surprised to see shares under pressure, as I think it is too early to go bottom fishing here just yet.

Analyse-artikel • May 10

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyse-artikel • Mar 12

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Investors who take an interest in Vapotherm, Inc. ( NYSE:VAPO ) should definitely note that the Independent Director...

Analyse-artikel • Mar 11

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Vapotherm, Inc. ( NYSE:VAPO ) shareholders have seen the share price descend 29% over the month. Despite this, the...

Analyse-artikel • Jan 19

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyse-artikel • Dec 14

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Potential Vapotherm, Inc. ( NYSE:VAPO ) shareholders may wish to note that insider Thomas Smith recently bought US$217k...

Analyse-artikel • Dec 11

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...

Rendement voor aandeelhouders

	VAPO	US Medical Equipment	US Markt
7D	0.5%	-3.6%	-1.5%
1Y	-22.2%	-15.8%	13.3%

Rendement versus industrie: VAPO presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -15.8 % opleverde.

Rendement versus markt: VAPO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 13.3 % opleverde.

Prijsvolatiliteit

Is VAPO's price volatile compared to industry and market?
VAPO volatility
VAPO Average Weekly Movement	1.7%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van VAPO is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van VAPO is het afgelopen jaar gedaald van 27% naar 2%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1993	182	Joe Army	www.vapotherm.com

Vapotherm, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Vapotherm zich tot de beurswaarde?
VAPO fundamentele statistieken
Marktkapitalisatie	US$13.61m
Inkomsten(TTM)	-US$54.42m
Inkomsten(TTM)	US$70.92m

0.2x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is VAPO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VAPO resultatenrekening (TTM)
Inkomsten	US$70.92m
Kosten van inkomsten	US$37.71m
Brutowinst	US$33.21m
Overige uitgaven	US$87.63m
Inkomsten	-US$54.42m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-8.71
Brutomarge	46.82%
Nettowinstmarge	-76.74%
Schuld/Eigen Vermogen Verhouding	-145.6%

Hoe presteerde VAPO op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/09/19 19:49
Aandelenkoers aan het einde van de dag	2024/09/19 00:00
Inkomsten	2024/06/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Vapotherm, Inc. wordt gevolgd door 5 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Robert Hopkins	BofA Global Research
Michael Gorman	BTIG
William Plovanic	Canaccord Genuity

This company has been acquired

Vapotherm (VAPO) Aandelenoverzicht

Risicoanalyse

Join community and earn perks

Vapotherm, Inc. Concurrenten

Trinity Biotech

NeuroMetrix

Scientific Industries

Cue Health

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.

Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023

Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Recent updates

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.

Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023

Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023

Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023

Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Vapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023

Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum Requirement

Vapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Vapotherm announces $23M private placement

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Vapotherm draws downgrade at William Blair after 2Q results

Price target decreased to US$4.83

Vapotherm: Out Of Air

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$34.33

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)

Chief Accounting Officer Joel Dube has left the company

Senior VP notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)

Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stock

Vapotherm: Hardly Breathing Room

Insider recently bought US$4.8m worth of stock

Independent Director Marina Hahn has left the company

Independent Chairman of the Board recently bought US$170k worth of stock

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Independent Director recently bought US$109k worth of stock

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day low: US$23.17

Senior VP & Chief Commercial Officer notifies of intention to sell stock

Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

New 90-day high: US$32.08

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Insider recently bought US$217k worth of stock

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Analysts update estimates

New 90-day low: US$23.44

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.49 loss per share

Price target lowered to US$42.67